Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Sangamo Therapeutics (NASDAQ:SGMOGet Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05), Zacks reports. Sangamo Therapeutics had a negative return on equity of 154.11% and a negative net margin of 1,749.06%. The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $8.51 million. During the same quarter in the prior year, the business earned $0.12 earnings per share.

Sangamo Therapeutics Stock Up 7.3 %

Shares of SGMO traded up $0.04 during midday trading on Friday, reaching $0.56. 4,769,970 shares of the stock were exchanged, compared to its average volume of 1,296,341. The business’s 50-day moving average price is $0.65 and its 200 day moving average price is $0.59. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.67.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. StockNews.com assumed coverage on Sangamo Therapeutics in a report on Saturday, April 27th. They issued a “sell” rating for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a report on Thursday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.67.

Read Our Latest Research Report on Sangamo Therapeutics

About Sangamo Therapeutics

(Get Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Read More

Earnings History for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.